Wordt geladen...
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAF(V600)-Mutated Nonmelanoma Tumors
BRAF(V600) mutations occur in multiple nonmelanoma tumors, but no US Food and Drug Administration–approved BRAF-targeted therapies exist for these cancers. BRAF inhibitor vemurafenib was recently found to demonstrate activity across various BRAF-mutated nonmelanoma cancer types. However, most tumors...
Bewaard in:
| Gepubliceerd in: | J Natl Cancer Inst |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Oxford University Press
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6059192/ https://ncbi.nlm.nih.gov/pubmed/29117359 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djx094 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|